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Summary
Objective: This white paper constitutes an overview of presentations and discussions from the 2nd annual osteoarthritis (OA) imaging
workshop.
Design: This workshop brought together the communities of basic OA researchers, orthopedists and rheumatologists, imaging scientists, in-
strument manufacturers, and pharmaceutical and regulatory representatives to try to identify those factors that have limited imaging [focusing
mostly on magnetic resonance imaging (MRI)] from making larger inroads into understanding and treating OA (‘‘why aren’t we there yet’’), and
to delineate future directions for success.
Results: The meeting was successful in raising awareness and questions about how we may proceed in this process. There was a general
consensus that a change in direction is needed for OA imaging research to succeed in yielding a better understanding of OA and development
of preventive and therapeutic procedures.
Conclusions: Our current paradigms are limiting the potential for MRI, by limiting how trials are designed and interpreted. Many basic ques-
tions remain in biology, pathophysiology, pain, and biomechanics; these questions need to be identiﬁed and speciﬁc imaging protocols need to
be developed to address them. The OA research communities need to work alongside the regulatory, pharmaceutical, and MRI industries to
support the new ideas and engage in the positive reinforcement of resources to further the new studies.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a highly prevalent disease associated
with severe functional disabilities in a large fraction of the
population. The impact of OA is expected to increase with
the exploding prevalence of obesity and the graying of
the ‘‘baby boomer’’ generation. Despite this concern, OA
remains a poorly understood disease, largely due to the dif-
ﬁculty in monitoring the disease in vivo. In the late 1980s,
the application of the superb soft tissue contrast of mag-
netic resonance imaging (MRI) to image the joint led to
great optimism that inroads to understanding the natural
history of, and applying therapeutics to, OA would be
quickly forthcoming. However, nearly 20 years later, much
about clinical OA has yet to be discovered, the mainstay
of current management is analgesic medication and total
joint replacement, there is yet to be a successful trial for
a disease-modifying OA drug (DMOAD), and radiography*Address correspondence and reprint requests to: Dr David J.
Hunter, New England Baptist Hospital, 125 Parker Hill Ave,
Boston, MA 02120, United States. Tel: 1-617-754-6655;
Fax: 1-617-754-5728; E-mail: djhunter@caregroup.harvard.edu
Received 22 October 2008; revision accepted 31 January 2009.
571is still the mainstay of imaging of OA for diagnostics and
clinical investigations.
The goal of the 2nd annual workshop on imaging in OA
was to bring together the communities of basic OA re-
searchers, orthopedists and rheumatologists, imaging sci-
entists, instrument manufacturers, and pharmaceutical
and regulatory representatives to try to identify those factors
that have limited imaging (focusing mostly on MRI) from
making larger inroads into understanding and treating OA
(‘‘why aren’t we there yet’’), and delineate future directions
for success. The workshop was held from June 25 to 28,
2008; 130 attendees participated, representing 12
countries.Where is ‘‘there’’?
In order to discuss ‘‘why aren’t we there yet’’, one must
ﬁrst deﬁne ‘‘there’’. ‘‘There’’ would be a situation in which
the signs of ‘‘pre-clinical’’ OA were detectable, with recom-
mended lifestyle and/or medical or surgical intervention to
prevent the disease from reaching a symptomatic level.
This would be comparable to other disease states such
as diabetes and cardiovascular disease, where one can de-
tect high glucose and/or glucose tolerance, high lipid levels,
572 D. Burstein and D. J. Hunter: Re-examining standard paradigms in imaging of OAatherosclerosis and hypertension, and treat the disease
precursors preemptively before these processes lead to
end-organ disease and failure.
Why aren’t we there yet?
Three main areas were discussed in terms of their contri-
bution to limiting MRI’s impact in understanding and treating
OA: (i) paradigm limitations, (ii) imaging what we can see in-
stead of what we want to see, and (iii) resource limitations
and industry/regulatory constraints.(I) PARADIGM LIMITATIONS: THE RED AND GREEN UNIVERSES
OF OAUntil now (and still), diagnosis and management of OA
rely mainly on the patient’s perception of pain and functional
limitations, and on radiographic evidence of disease. Sev-
eral strong paradigms have resulted from viewing the dis-
ease in this light, and the idea was put forth that these
paradigms and associated dogma are limiting how we cur-
rently design studies, view the data, and how we interpret
the implications for clinical trials, ultimately limiting MRI’s
utility.
As a means of discussion, we refer to those paradigms
resulting from our current frame of reference (pain and ra-
diographs deﬁning the disease) as being in the ‘‘red uni-
verse’’. An alternate universe, or the ‘‘green universe’’
would be that in which study design and interpretation
would not have limitations based on the notions of the red
universe.
In the red universe, OA is seen as a progressive degen-
erative disease of cartilage loss; therefore radiography is
the primary tool for imaging OA, and the information ob-
tained feeds back to further supporting the notion of OA be-
ing primarily a disease of cartilage loss. In the green
universe, the paradigm is that OA is a reversible disease
of multiple tissues of the joint. Consequently, MRI (and
other imaging modalities) might be utilized to interrogate dif-
ferent molecular parameters of joint structures to investigate
early disease, which may further elucidate how to prevent
and/or treat early ‘‘pre-clinical’’ disease, i.e., before it is
symptomatic. Some of the paradigms and associated limita-
tions and opportunities of the red and green universes, re-
spectively, are in Tables I and II.
As an example, because the current paradigm is to deter-
mine the efﬁcacy of a DMOAD by evaluating its ability to de-
crease the rate of progression of cartilage loss by
radiography (and more recently by MRI), entry into clinical
trials is generally focused on those individuals who might
be ‘‘fast progressors’’, i.e., those who may lose cartilage
quickly. Many times, this limits candidates to those with
level Kellgren & Lawrence (KL) grade 2 or 3 disease as
seen by radiography.
An example of the image of a knee from such an individ-
ual is shown in Fig. 1(a). While this individual may lose car-
tilage quickly, much of the cartilage is already lost. Would
this be the best candidate to be helped by a DMOAD? Con-
versely, the individual shown in Fig. 1(b) is one who is
asymptomatic, and has a radiographic KL grade of 0. How-
ever, by the MRI scan, there are clearly areas of cartilage
degeneration. Should this individual be a ‘‘control’’ subject
for a DMOAD trial?
Future efforts need to be targeted to delineating what
early/preclinical disease is, and delineating these individ-
uals so future efforts for structural preservation can be tar-
geted toward them. At present we have neither a deﬁnitionof early disease nor efﬁcacious therapy and it is likely that
we need to develop the deﬁnition, and a reliable and
responsive means of tracking their progression before we
will have effective therapy. In the ﬁrst instance these
deﬁnitions of early disease might be developed in injury
cohorts and in persons without established disease from
observational cohorts.
The implications are that many of the DMOAD trials may
have ‘‘failed’’ due to waiting too long in the course of dis-
ease to intervene, and thereby also not testing the interven-
tion on the group potentially most likely to beneﬁt from it. As
preclinical efﬁcacy has generally been assessed in animal
models without extensive damage at the time of instituting
the agent, yet this is then tested in the human model in per-
sons with late stage disease, it is not surprising that many
trials fail to replicate their preclinical data. Other reasons
for failure to replicate preclinical data include poor pre-clin-
ical models and species differences. In addition, grouping
cohorts by KL grade may include joints which have OA at
the molecular level in the ‘‘control’’ group and hence con-
founding data interpretation.
Throughout the conference attendees provided input
through comment cards on ‘‘red and green’’ concepts;
a few examples are given in the Appendix; the entire range
of comments can be found on the website (http://nebh.org/
display.asp?node_id¼10649).(II) IMAGING WHAT WE WANT TO SEE, INSTEAD OF SEEING
WHAT WE CAN IMAGEAs a community, we have been taking tools available to
us in imaging, and using them to try to image the joint.
The most obvious impact has been in the reliance on radi-
ography to delineate the level of disease for OA. However,
this is true for much of the effort thus far in MRI, where the
attention has been on applying MRI metrics utilized for other
disease areas to OA (Fig. 2).
Many of the tissues of the joint are unlike those of other
organ systems in a number of inherent and important
ways. For example, many MRI contrast mechanisms are
dependent upon the cellular/interstitial volume ratios; articu-
lar cartilage is almost acellular, and therefore these contrast
mechanisms may not be applicable to the study of cartilage.
Furthermore, in most other systems, the function of the or-
gan is that of cellular function, i.e., cellular contraction, ﬁlter-
ing, electrical transmission; however in the joint the function
of the tissues is biomechanical, and is generally provided by
the characteristics of the extracellular matrix itself (although
the cells are responsible for producing that matrix). As a re-
sult, many of the indices and contrast mechanisms which
have been utilized for other body systems may not provide
the information/contrast needed to study OA.
In an effort to further the ﬁeld the workshop consisted of
a series of presentations focused on the biology, patho-
physiology, pain, and biomechanics of OA. The intent of
these introductory presentations was to lay a platform for
what we currently know about OA. Having established this
platform the workshop participants helped identify those
questions which need to be addressed, potentially through
existing or new imaging protocols. Some of the main points
are brieﬂy summarized here:
What is OA?
The question was ﬁrst asked to redeﬁne OA in order to
facilitate further discussion within the workshop. The partic-
ipants at the workshop generated this new deﬁnition
Table I
Red Universe
Paradigm Resulting limitations
OA is a disease of cartilage loss  Radiography is appropriate for deﬁning disease level.
 Radiography is appropriate for monitoring impact of therapeutics.
 Cohort delineation for clinical trials should be along the lines of radiographic
criteria (JSN, KLG).
 DMOADs should focus on targeting cartilage.
OA is progressive  Biomarkers can only be useful in clinical trials if they are able to demonstrate
progression of disease in a natural history trial.
 Entry criteria for intervention trials should be those with KL 2 or 3, ‘‘fast progressors.’’
 Biomarkers for therapeutic development should be evaluated on the basis of
decreasing progression.
Patients seek medical help due to pain  Intervention should be pain alleviation.
573Osteoarthritis and Cartilage Vol. 17, No. 5cognizant of prior deﬁnitions of OA and their respective lim-
itations, including those proposed in 1986 and 1995 in
Workshops on the etiopathogenesis of OA sponsored by
the National Institute of Arthritis, Diabetes, Digestive, and
Kidney Diseases, the National Institute on Aging, the Amer-
ican Academy of Orthopaedic Surgeons, the National
Arthritis Advisory Board and the Arthritis Foundation.
The deﬁnition proposed for use at this workshop was the
following:
‘‘OA isadiseaseof diarthrodials joint(s) that is character-
ized by changes in multiple tissues including bone, liga-
ments, synovium, meniscus, muscle and cartilage, is
modulated by biologic and biomechanical processes,
whose morphologic and molecular changes in joint
structures can be visualized by imaging abnormalities,
and when clinically manifest, is characterized by pain,
functional impairment and disability.’’
Biology
Normal joint tissues, cartilage, synovium, bone, tendons,
ligaments and the meniscus, maintain a functional extracel-
lular matrix that replaces itself very slowly and provides a va-
riety of functions in the joint. In OA, the cells become
metabolically hyperactive, synthesizing both anabolicTable I
Green Univ
Paradigm
OA is a disease of multiple tissues  DMOADs can be tar
 MRI can target early
on different tissues
OA is reversible  Detecting early disea
 Biomarkers do not n
they may be stable i
disease with therape
Disease is detectable and treatable before
pain becomes limiting and before gross
tissue is lost
 Entry criteria for clini
 Physicians can treatcomponents (signaling and matrix molecules) and catabolic
components (nitric oxide and matrix metallo-proteinases).
Recent studies have focused on the articular cartilage,
which has similarly been the focus of imaging. Some impor-
tant observations are as follows:
The chondrocytes synthesize both degradative enzymes
and matrix-building macromolecules implying that the cells
are taking on the task of repair as well as degeneration
(Fig. 3). The contribution of inﬂammatory molecules may
be more signiﬁcant than was originally thought, and a spe-
ciﬁc pattern of chemokines may provide a molecular ‘‘ﬁnger-
print’’ to identify cells in the initial stages of response. The
cells through the depth of the cartilage (from superﬁcial to
deep cells) do not display the same pattern of gene expres-
sion, indicating that there may be more than one mecha-
nism responsible for increased gene expression. The cells
in the superﬁcial zone ‘‘dedifferentiate’’ making large
amounts of type III collagen and ﬁbronectin while the cells
in the middle and deep zones make predominantly cartilag-
inous extracellular matrix molecules. This difference in gene
expression will yield a different kind of matrix and, poten-
tially, the superﬁcial cells may become more susceptible
to erosion. These observations will likely apply to many of
the other joint tissues, with synovium and bone likely to
be even more metabolically active.I
erse
Resulting opportunities
geted at different tissues which may be more responsive.
disease and the efﬁcacy of therapeutics through the impact
se may prevent the longer-term pain and functional limitations.
eed to demonstrate progression of disease in natural history trials;
n natural history trials and demonstrate regression (healing) of
utic interventions.
cal trials need to be those that delineate pre-radiographic disease.
‘‘pre-clinical’’ disease.
Fig. 1. Example of implications of red and green universe paradigms: are appropriate individuals being enrolled into clinical trials? In the ‘‘red
universe’’, individuals with grade KL 3 would be enrolled in clinical trials for DMOAD development, on the basis that they would be ‘‘fast pro-
gressors’’, i.e., likely to lose cartilage quickly, and therefore measurably in a short period. The DMOAD would be expected to slow down that
rate of progression. The image on the left is a dGEMRIC image from a knee with such characteristics. While the cartilage may continue to
decrease in this compartment, it may not be the situation amenable to response to a therapeutic intervention. Similarly, the image in (b) is
a dGEMRIC image of a knee with a rating of KL 0, and normal joint space. This individual would be enrolled as a ‘‘control’’ subject; however,
there are clearly areas of degeneration compared with the image in (c), of a knee with a similar radiographic grade. Grouping all of the indi-
viduals without radiographic evidence of disease, i.e., those from groups (b) and (c) together, may be mixing disease and true control groups,
making data interpretation misleading. Furthermore, the knee in (b) may be able to respond to a DMOAD better than the knee shown in (a).
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izing the repair process and the inﬂammatory process, as
well as the degenerative process, in the setting of OA.
Pathophysiology
As described above, articular cartilage is the tissue that
has attracted most attention in relation to the pathogenesis
of OA, largely because of the striking changes seen in this
tissue in advanced OA. The chondrocentrists might even ar-
gue that there is no such thing as OA without cartilage
changes.
Concomitant events in bone are less well understood, but
include the development of osteophytes through ossiﬁca-
tion of cartilage outgrowths, and changes in the vascularityFig. 2. We have been ‘‘seeing what we can image’’ instead of ‘‘imaging wh
radiography, or our current MRI imaging protocols adopted from other app
of cartilage. When we are not successful at better elucidating OA, we ha
lution). However, we need to adjust our methodology to ﬁnding the tools
and other tissuesand turnover of the subchondral bone. Subchondral bone
changes may be an important part of pathogenesis of pro-
gressive joint destruction, in part because the bone has
far greater ability to repair, adapt and change the shape
of the joint than cartilage. Whether events in cartilage pre-
cede those in bone, are concomitant with them, or whether
subchondral bone changes can actually cause early carti-
lage damage in OA is uncertain.
Several of the most potent risk factors for OA are me-
chanical. Recent studies have stressed the importance of
muscle weakness, joint instability and malalignment as pos-
sible causes of OA. Ligamentous instability is also an early
feature of OA, in the knee exempliﬁed by early changes in
the menisci and ligaments. Do these changes precede
those in cartilage, are they concomitant, or do they follow?at we need to see’’: until now, the approach taken has been to utilize
lications, to the study of OA. Most of the focus has been on imaging
ve made fancier techniques (better pulse sequences, higher reso-
with which to answer compelling questions in OA of both cartilage
of the joint.
Age
Genetics
Systemic
Factors
Predisposition
to OA
Joint
Biomechanics
Biochemical Pathways
(cytokines, proteases, etc.)
Site and Severity of OA
Pain
DistressDisability
Injury
Overload
Instability
Fig. 4. The pathophysiology of OA undoubtedly involves both ge-
netic and systemic factors, as well as internal and external biome-
chanical factors. One needs to take all these factors into account
in trials of OA, if we are to be successful in intervening in the dis-
ease process. Reproduced with permission from the Lancet and
authors from Fig. 4 sourced from Dieppe PA, Lohmander LS.
Pathogenesis and management of pain in osteoarthritis. Lancet
2005:365:965e73.
Fig. 3. The biology of OA is recognized to be a combination of both
anabolic components (signaling and matrix molecules) and
catabolic components (nitric oxide and matrix metallo-proteinases).
While prior imaging studies have focused on the situations where
the catabolic components over-ride the anabolic, techniques should
be sought which will visualize the reparative aspects of joint
physiology as well.
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different pathogenic pathways in OA. With disease modiﬁ-
cation in OA as a goal, compounds targeting proteinases,
inﬂammation pathways, and bone metabolism are being
tested in the laboratory, in animal models, and in clinical tri-
als. Implicit in the concept of OA disease modiﬁcation is the
idea that outcome measured as a reduction of structural
joint damage will translate into symptomatic beneﬁts and
improved quality of life for the patient. This concept remains
unproven. Even if and when proven, it is unlikely to be effec-
tive in joints with adverse biomechanics due to e.g., mala-
lignment or ligamentous insufﬁciency.
Imaging,might, therefore contribute by focusingmoreatten-
tion on multiple tissues of the joint, and multiple pathophysio-
logic contributing pathways (biologic and biomechanical) in
order to better understand the pathophysiology of OA (Fig. 4).
Pain
Pain is a subjective experience, involving both sensory
and emotional dimensions. In particular, ascending and de-
scending neural pathways may be inﬂuenced by genetic
factors as well as a large number of other endogenous
(e.g., mood) or exogenous (e.g., psychotropic medication)
factors. These complex interactions contribute to individual
differences in pain perception and behavioral pain re-
sponses, as well as the only modest associations between
pain ratings and disease severity ratings.
One important alteration in the function of the ascending
neural pathways, central sensitization produces exagger-
ated pain responses to low intensity stimuli. There is evi-
dence that central sensitization and psychosocial factors
(e.g., ethnic background) affect pain responses in patients
with OA. However, few investigators have used neurosci-
ence methods, such as quantitative sensory testing and
neuroimaging, to test hypotheses concerning the inﬂuence
of these factors on pain augmentation or inhibition among
these patients.
Barriers to progress in pain research in OA include limita-
tions in (a) communication between neuroscientists and
rheumatologists; (b) education in pain mechanisms for
medical students, residents, and fellows; and (c) availability
of quantitative sensory testing and neuroimaging resources.Applying more recent imaging advances in neurological
imaging to better understand pain perception in the setting
of OA may both aid in ﬁnding better therapeutics for analge-
sia, as well as a better understanding of the connection (or
lack thereof) between pain and structural disease.
Biomechanics
There is little doubt that mechanics play a role in the ini-
tiation, progression and successful treatment of OA. How-
ever, we don’t yet know enough about which speciﬁc
mechanical parameters are most important and what their
impact is on the disease process to make comprehensive
statements about how mechanics should be modiﬁed to
prevent, slow or arrest the disease process, nor how the
inﬂuence of biomechanics should be optimally measured.
There are a number of hypotheses about the links be-
tween mechanics and OA, and these hypotheses deﬁne
the mechanical quantities of primary interest to researchers.
Unfortunately, the most interesting quantities are among the
most difﬁcult to measure. While force, force distribution and
loading rate ﬁgure most prominently in mechanical hypoth-
eses about OA, they cannot currently be measured in vivo.
A number of different approaches have been described that
use MRI to assess three-dimensional joint kinematics in vivo.
They are distinguished from each other by whether theymea-
sure two-dimensional or three-dimensional movement,
whether kinematics is measured when the joint is actively
loaded, and whether the movement is measured continu-
ously. No onemethodmeasures three-dimensional joint kine-
matics continuously in physiologically-loaded motion.
However,MRImight beable tomeasuremolecular andstruc-
tural long-term effects of different biomechanical conditions or
interventions, once these are identiﬁed as being of interest.(III) RESOURCE LIMITATIONS AND INDUSTRY/REGULATORY
CONSTRAINTSPerspectives from pharmaceutical industry
One of the perceived constraints to DMOAD development
is the current regulatory approval process. The US Food
576 D. Burstein and D. J. Hunter: Re-examining standard paradigms in imaging of OADrug Administration (FDA) developed guidance describing
an OA (OA) drug development ‘‘roadmap’’, which has
been in draft format since 1999 (http://www.fda.gov/Cber/
gdlns/osteo.htm). This guidance describes a process for
drug approval for speciﬁc indications in OA, including treat-
ment of symptoms, delays in structural progression and
even discusses prevention of OA. Radiographic measure-
ment of joint-space narrowing is currently recommended
in the FDA guidance documents as the imaging endpoint
for clinical trials of DMOADs. At present, an alteration in
structural progression would likely be determined by X-
ray, but it is possible that newer technologies may include
MRI or even ultrasound once appropriately validated. Cur-
rently the approval of potential therapies in OA requires
that this structural alteration be linked to some clinical ben-
eﬁt either at the time when the structure was measured or at
a later time-point. At present no products have been ap-
proved for structure modifying effects even as an adjunctive
claim. It is also important to note that the guidance state-
ment is currently being revised by an Osteoarthritis Re-
search Society International (OARSI)eFDA working group.
Some suggest that if we were able to create the ideal bio-
marker (simple: relatively easy to perform, preferably non-
invasive. Reliable: reproducible and standardizable across
multicenters. Sensitive to change: changes can be detected
in a relatively small population and in a relatively short pe-
riod of time, changes reﬂect disease progression not just
aging. Clinically relevant: changes in marker should trans-
late into improved, meaningful clinical outcomes, changes
should be biologically understood and relevant to the dis-
ease process) for a clinical trial we would overcome these
limitations. We are some way from having the ideal bio-
marker available. Development of such a biomarker may
be accelerated by the combined efforts of the different com-
munities involved in OA research.
Constraints of imaging manufacturers
In order to diagnose and monitor the development of OA
it is necessary to have an accurate and reproducible diag-
nostic system that reﬂects both the macroscopic and the
biochemical status of the tissues of the joint. While MRI
has the potential to ﬁll that role, the clinical use of the cur-
rent MRI methods has been limited as there are only rudi-
mentary packages available by the manufactures for
widespread use of these techniques.
Both technical and resource issues have limited the wide-
spread implementation of MRI of the joint into standard MRI
packages. Cartilage, which has been the main target struc-
ture for imaging OA, requires very high resolution imaging
due to its thin and curved anatomy. Therefore it is not al-
ways possible to directly implement packages designed
for applications of other areas such as the brain. The ability
to image the role of bone, soft tissue structures and inﬂam-
mation parallel to cartilage using different techniques and
applications within a practical time limit in one imaging ses-
sion is challenging.
The relative lack of resources being put into solving these
problems results from a number of issues such as manufac-
turer’s interest, funding, and business targets. Neurology or
cardiac packages are seen as a larger market for MRI, and
therefore aremore targeted by themanufacturers and as a re-
sult a wide range of techniques, applications and packages al-
ready exist. As the manufacturer’s interests are driven by
a business model, the question is why imaging OA has not
been seen as a potential market. Another issue inﬂuencing
the decision of which package to buy, and therefore drivingMRI development, is research funding; fewer groups are
working on MRI of OA than many of the other areas. Finally,
due to the lack of an effective DMOAD or other intervention
until late stage disease, physicians are less involved in early
treatment of OA, and therefore the pressure from the physi-
cian’s side for improved diagnostics is limited. Certainly if
we had a means of detecting and monitoring early disease
in the presence of an effective DMOAD and that this imaging
biomarker was able to be applied widely imaging companies
would likely be very interested.
To overcome these limitations the importance of develop-
ing effective imaging packages for OA that can be distrib-
uted to clinical groups needs to be communicated with the
imaging manufacturers. Only then will we as a community
be able to break the ‘‘catch-22’’ of the inability to effectively
image OA, thus limiting the development of therapeutics,
and further reducing the motivation for further imaging.
How do we get there?
Getting to the point of recognizing the risk factors and early
signs of OA and intervening with lifestyle, medical, and/or
surgical interventions to prevent the disease from becoming
disabling will require a change of mindset as well as multiple
new research programs to address the new paradigms. As
Confucius simply stated: ‘‘A journey of a thousand miles be-
gins with a single step.’’ The imaging workshop constituted
the ﬁrst step on this journey and was successful in raising
awareness and questions about how we may proceed in
this process. Based on discussions of the workshop, there
is a general consensus that a change in direction is needed
for OA imaging research to succeed in yielding a better un-
derstanding of OA and development of preventive and ther-
apeutic procedures. Our current paradigms are limiting the
potential for MRI, by limiting how trials are designed, and in-
terpreted. Many basic questions remain in biology, patho-
physiology, pain, and biomechanics; these questions need
to be identiﬁed and speciﬁc imaging protocols need to be de-
veloped to address them. The OA research communities
need to work alongside the regulatory, pharmaceutical, and
MRI industries to support the new ideas and engage in the
positive reinforcement of resources to further the new stud-
ies. Emboldened by our interactions it is our opportunity to
address these many challenges and strive for the situation
of removing OA as a source of disability.
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Red and green universe concepts
 ‘‘OA is a disease of many etiologies ending in a com-
mon pathway of progressive joint failure. Different tar-
geted (early) therapies will be needed to take into
account these different etiologies such as trauma, over-
load, genetics, nutritional factors, etc. What we call OA
now is the late stages of a multi-factorial etiopathoge-
netic complex.’’
 ‘‘The current approach of asking that a drug reverse
structural OA is somewhat like requiring a drug for
stroke to reverse paralysis months after a thrombotic
event.’’
 Biomarker development is driven largely by the pharma
universe; ‘‘if there is a disease, ﬁnd a drug for it, if there
is a drug, ﬁnd a disease for it’’. Should we to a larger
degree consider biomarkers that would help us identify
those who would best beneﬁt from better analgesia,
beneﬁt from weight loss, beneﬁt from muscle training,
etc? Would these be the same biomarkers as those
which we currently seek?
 ‘‘Molecular level imaging will allow us to understand the
biochemical alteration in cartilage, i.e., image earlier in
OA pathway.’’
 ‘‘The discussion today shows me there is some discon-
nect between basic science, physicists, clinicians, and
radiologists. We need work as a primary team. The rea-
son is that each group is asking different questions or is
looking at OA from different perspectives. There has to
be a uniﬁed approach so that the results can be applied
to all individual subspecialists.’’
 ‘‘Looking for changes in pre-deﬁned regions is wrong!
Very heterogeneous disease process, and regional
changes are very sensitive to the location of
boundaries.’’
 ‘‘Cartilage thickness measurements are not important
or useful as an early imaging biomarker.’’
 Can we achieve a level of understanding/intervention
such that the disease is diagnosed/halted before pain
and functional loss ensues?
 How much of our knowledge is limited by the metrics
used (i.e., is the disease considered irreversible be-
cause we only see that aspect of it?)?Definition of OA
 ‘‘Let’s not get hung up on what the deﬁnition of OA is, or
what imaging criteria to diagnose it should be, we might
get pigeon holed.’’
 ‘‘Deﬁnition of OA: depends on the point of view.. Pa-
tient: pain, decreased function. Surgeon: X-ray, need
for surgery. Radiologist: changes in MRI, dGEMRIC. Bi-
ologist: imbalance of cartilage turnover. Biomechanics:
malalignment leading to functional impairment. For me/
us: integral of all above named.’’
 ‘‘It is not and should not be our job todeﬁneOA.Weshould
instead deﬁne the populations that would be prudent to
study for different types of DMOADs. This deﬁnition may
only partially overlap/intersect with the OA deﬁnition.’’
Biology
 ‘‘Are there regional variations in the permeability of the
subchondral bone?’’
 ‘‘If we can’t image a targeted biomarker in articular car-
tilage due to difﬁculty in getting the targeted contrast
agent in, can we image its effect on meniscus or a differ-
ent tissue of the joint?’’
 ‘‘Can we image cell death in cartilage?’’
 ‘‘Can we change the vocabulary to talk about the super-
ﬁcial layer as ‘vulnerable cartilage’, in analogy to the
‘vulnerable plaque’ from vascular medicine?’’
Pathophysiology
In the discussions following, a number of potential patho-
physiology research topics and comments were obtained
from workshop attendees and included:
 ‘‘Can we prevent meniscal extrusion?’’
 ‘‘What is a bone marrow lesion (BML) lesion in OA
(water, cells, blood)?’’
 ‘‘Are people with very early OA given a (mistaken) ﬁbro-
myalgia (FM) diagnoses? e Particularly in younger
people; should we be investigating so-called FM pa-
tients more thoroughly with MRIs in order to ﬁnd the
very early stages of OA disease? This would include
multiple joints (hips, knees, back).’’
 Atwhat point can tissue/joint still be repaired to pre-injury
or pre-disease state, i.e., is the disease fully reversible?
Pain
 Pain blocking interventions: we know that patients ti-
trate their activities to help control their knee pain.
Pain probably serves a joint protective function. What
are the implications for developing pain blocking inter-
ventions? When activity changes no longer help control
pain, is it too late to inﬂuence the cause of the disease?
 We can learn a lot about pain from persons with struc-
tural disease who do not have pain. What is unique or
different about persons with structural changes consis-
tent with OA that do not have symptoms?
 What are the predominant reasons people seek clinical
care for osteoarthritis? Is it pain or functional limitation
and should interventions target the predominant com-
plaint?Forexample if a personﬁnds it difﬁcult towalk treat
the joint complaint as opposed to analgesing the patient.
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 ‘‘The distinction between ﬁrst degree and second de-
gree OA: secondary OA, abnormal load on normal tis-
sue, therefore cannot expect to reverse without solving
biomechanical problem; primary OA, normal load on
abnormal tissue e what are the predisposing factors?’’
 ‘‘Are some people born with a joint shape that will give
them OA?’’
 How do we design studies that link mechanics with
other imaging-based measures of OA?
 ‘‘How can physical rehabilitation inﬂuence OA progres-
sion? Does the deﬁnition of early OA allow the selection
of cohorts for relief interventions that are more homoge-
neous and therefore more likely to show successful
outcomes?’’
 Can we determine at what point the biomechanics over-
rides biological mechanisms?
Constraints
 Given that one of the difﬁculties in testing DMOADs is
due to the long timecourse of OA development, it might
make sense to test these pharmaceuticals in a group
who can potentially beneﬁt on the short term, e.g.,those with injuries who are either recovering with phys-
ical therapy and/or those undergoing surgical interven-
tion. The point would be to limit the degeneration/
improve healing immediately after the injury and/or after
surgery, to allow for better immediate repair and avoid
the long-term sequellae of injury.
 Should we use a sports model injury of disease for
DMOAD development?
 How do we develop ubiquitous software packages for
image registration and image segmentation that are
fast, accurate with minimum user interaction?
 Except for cost, MRI is an ideal screening modality e
can we do a 5-min MRI exam cheaply (aka screening
mammogram) to detect and characterize OA (much
more helpful when a DMOAD exists)?
 What use will improvements in imaging/diagnosis/
understanding of OA process etc., be if info doesn’t
get to front lines, i.e., Primary care physicians and
healthcare providers? Method of dissemination is
necessary.
 Musculoskeletal radiologists often describe degenera-
tive changes of OA in terms of morphology such as
a ‘‘ﬂattening of the tibial plateau.’’ What algebraic or im-
aging technologies should we be exploring to capture
and measure these changes?
